TCRX Earnings TScan Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q1 2026 | 2026-03-31 | -0.22 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -1.00 | 2026-03-04 | 10-K |
| Q3 2025 | 2025-09-30 | -0.82 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.55 | 2025-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.26 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -1.14 | 2026-03-04 | 10-K |
| Q3 2025 | 2024-09-30 | -0.84 | 2025-11-12 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.59 | 2025-08-12 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.32 | 2025-05-06 | 10-Q |
| FY 2024 | 2023-12-31 | -1.36 | 2025-03-05 | 10-K |
| Q3 2024 | 2023-09-30 | -1.25 | 2024-11-12 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.30 | 2024-08-12 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.93 | 2024-05-13 | 10-Q |
| FY 2023 | 2022-12-31 | -2.75 | 2024-03-06 | 10-K |
| Q3 2023 | 2022-09-30 | -1.98 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.30 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.67 | 2023-05-10 | 10-Q |
| FY 2022 | 2021-12-31 | -4.17 | 2023-03-08 | 10-K |
| Q3 2022 | 2021-09-30 | -4.55 | 2022-11-09 | 10-Q |
| Q2 2022 | 2021-06-30 | -14.25 | 2022-08-10 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.